Preclinical Toxicity and Safety of MM-129—First-in-Class BTK/PD-L1 Inhibitor as a Potential Candidate against Colon Cancer

MM-129 is a novel inhibitor targeting BTK/PI3K/AKT/mTOR and PD-L1, as it possesses antitumor activity against colon cancer. To evaluate the safety profile of MM-129, we conducted a toxicity study using the zebrafish and rodent model. MM-129 was also assessed for pharmacokinetics features through an...

Full description

Bibliographic Details
Main Authors: Justyna Magdalena Hermanowicz, Bartlomiej Kalaska, Krystyna Pawlak, Beata Sieklucka, Joanna Miklosz, Mariusz Mojzych, Dariusz Pawlak
Format: Article
Language:English
Published: MDPI AG 2021-08-01
Series:Pharmaceutics
Subjects:
Online Access:https://www.mdpi.com/1999-4923/13/8/1222